Results 151 to 160 of about 1,844 (180)

Mavacamten for treatment of symptomatic mid-ventricular obstruction in hypertrophic cardiomyopathy: a case report. [PDF]

Eur Heart J Case Rep
Hunziker S, Haaf P, Vischer AS.
europepmc   +1 more source

Mavacamten for symptomatic obstructive hypertrophic cardiomyopathy

Australian prescriber
openaire   +3 more sources

SarcGraph for High-Throughput Regional Analysis of Sarcomere Organization and Contractile Function in 2D Cardiac Muscle Bundles. [PDF]

MicroPubl Biol
Mohammadzadeh S, Tsan YC, Renberg A, Kobeissi H, Helms A, Lejeune E.   +5 more
europepmc   +1 more source

Correction: Safety and Effectiveness of Mavacamten Use in Hypertrophic Obstructive Cardiomyopathy: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Alharbi TY, Alnadawi HA, Almutairi GM, Altheyab FY, Aldoweesh OH, Alfehaid OS, Alhaj AA, Alotaibi AM, Al Zweihary AM.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Mavacamten—A Targeted Therapy for Hypertrophic Cardiomyopathy

Journal of Cardiovascular Pharmacology, 2023
Abstract: The pathophysiology of hypertrophic cardiomyopathy is primarily comprised of dynamic left ventricular outflow tract obstruction, mitral regurgitation, and diastolic dysfunction. Symptoms such as dyspnea, angina, or syncope can occur because of left ventricular (LV) hypertrophy and reduced LV cavity size.
Ashley, Schenk, Nathan, Fields
openaire   +2 more sources

New Era: Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Cardiovascular & Hematological Agents in Medicinal Chemistry, 2023
Abstract: Obstructive hypertrophic cardiomyopathy results from asymmetric septal hypertrophy, which eventually obstructs the outflow of the left ventricle. Obstructive hypertrophic cardiomyopathy is linked to mutations in genes that encode for sarcomere proteins, including actin, β-myosin heavy chain, titin, and troponin.
Rami A. Al-Horani, Ma’Lik Woodland
openaire   +2 more sources

Mavacamten (Camzyos)

Canadian Journal of Health Technologies, 2023
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire   +1 more source

Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy

Annals of Internal Medicine, 2019
Mavacamten, an orally administered, small-molecule modulator of cardiac myosin, targets underlying biomechanical abnormalities in obstructive hypertrophic cardiomyopathy (oHCM).To characterize the effect of mavacamten on left ventricular outflow tract (LVOT) gradient.Open-label, nonrandomized, phase 2 trial. (ClinicalTrials.gov: NCT02842242).5 academic
Stephen B, Heitner, Daniel, Jacoby, Steven J, Lester, Anjali, Owens, Andrew, Wang, David, Zhang, Joseph, Lambing, June, Lee, Marc, Semigran, Amy J, Sehnert   +9 more
openaire   +2 more sources

Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy

Clinical Therapeutics
Hypertrophic cardiomyopathy (HCM) is an under-recognized genetic cardiac disorder affecting the muscles and contractility of the heart, which in turn can result in heart failure symptoms, arrhythmia, and sudden cardiac death. Previously, pharmacotherapy options for HCM were not disease-specific, often poorly tolerated, and overall inadequate for ...
J. Chase Cole, Samantha F. Benvie, Marci DeLosSantos   +2 more
openaire   +2 more sources